Table 3 OCT characteristics at baseline for morphological responders and non-responders to one intravitreal bevacizumab injection
|  | Responders (n = 22) | Non-responders (n = 30) | p-value |
|---|---|---|---|
Vitreous status, n (%) | Â | Â | Â |
 Completely attached | 1 (4.8) | 1 (3.6) | 0.8 |
 VMA | 1 (4.8) | 8 (28.7) | 0.03 |
 VMT | 1 (4.8) | 2 (7) | 0.73 |
 Completely detached | 18 (85.6) | 17 (60.7) | 0.055 |
ERM, n (%) | 14 (63.6) | 13 (43.3) | 0.15 |
 Thick ERM | 1 (7.1) | 3 (23.1) | 0.47 |
 Thin ERM | 13 (92.9) | 10 (76.9) | 0.065 |
Intraretinal cysts, n (%) | Â | Â | Â |
 Ganglion cell layer | 5 (22.7) | 4 (13.3) | 0.38 |
 Inner nuclear layer | 21 (95.5) | 22 (73.3) | 0.037 |
 Outer plexiform layer | 2 (9.1) | 4 (13.3) | 0.64 |
 Outer nuclear layer | 22 (100) | 25 (83.3) | 0.07 |
 Elongated shape | 15 (68.2) | 17 (56.7) | 0.4 |
 Polygonal shape | 18 (81.8) | 23 (76.7) | 0.65 |
 Round shape | 12 (54.5) | 10 (33.3) | 0.13 |
 Hyporeflective | 8 (36.4) | 6 (20) | 0.19 |
 Isoreflective | 0 (0) | 2 (6) | 0.22 |
 Hyper-reflective | 0 (0) | 0 (0) |  |
 Mixed reflectivity | 14 (63.6) | 18 (60) | 0.79 |
Hyper-reflective foci, n (%) | 17 (77.3) | 23 (76.7) | 0.96 |
 Intracystic | 13 (59.1) | 21 (70) | 0.71 |
 Non-cystic | 16 (72.7) | 21 (70) | 0.83 |
Exudates, n (%) | Â | Â | Â |
 Absent | 2 (9.1) | 2 (6.7) | 0.75 |
 < 5 present | 18 (81.8) | 21 (70) | 0.33 |
 > 5 present | 2 (9.1) | 7 (23.3) | 0.18 |
DRIL, n (%) | Â | Â | Â |
 No | 12 (54.5) | 20 (66.7) | 0.38 |
 Yes | 10 (45.5) | 10 (33.3) |  |
ELM disruption, n (%) | Â | Â | Â |
 No | 19 (86.4) | 26 (86.7) | 0.98 |
 Yes | 3 (13.6) | 4 (13.3) |  |
EZ disruption, n (%) | Â | Â | Â |
 No | 14 (63.6) | 22 (73.3) | 0.45 |
 Yes | 8 (36.4) | 8 (26.7) |  |
Subretinal fluid, n (%) | Â | Â | Â |
 No | 12 (54.5) | 26 (86.7) | 0.01 |
 Yes | 10 (45.5) | 4 (13.3) |  |
 Hyporeflective | 7 (70) | 3 (75) | 0.85 |
 Isoreflective | 0 (0) | 0 (0) |  |
 Hyper-reflective | 0 (0) | 0 (0) |  |
 Mixed reflectivity | 3 (30) | 1 (25) | 0.85 |